Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAbramson Cancer Center at Penn Medicine
About this trial
* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla
Eligibility criteria
Qualifiers
Participants will be ≥ 18 years of age
New contrast-enhancing lesion or lesions showing increased enhancement (>25%increase) in a patient with a historical diagnosis of glioblastoma (histologic or molecular proof) on standard MRI after completion of treatment
Recommended for clinically indicated surgical resection
Life expectancy of greater than 3 months in the opinion of an investigator or treating physician.
Disqualifiers
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
Females who are pregnant or breastfeeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential prior to injection.
Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
Contraindications to MRI
Trial design
Treatments tested in this trial
- Fluciclovine F18
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Abramson Cancer Center at Penn Medicine
Lead sponsor
University of Pennsylvania
Sponsor institution
Source ClinicalTrials.gov